KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Ratio (2016 - 2025)

Biomarin Pharmaceutical's Equity Ratio history spans 17 years, with the latest figure at 0.8 for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 0.99% year-over-year to 0.8, compared with a TTM value of 0.8 through Dec 2025, down 0.99%, and an annual FY2025 reading of 0.8, down 0.99% over the prior year.
  • Equity Ratio for Q4 2025 was 0.8 at Biomarin Pharmaceutical, up from 0.8 in the prior quarter.
  • The five-year high for Equity Ratio was 0.81 in Q1 2025, with the low at 0.71 in Q4 2021.
  • Average Equity Ratio over 5 years is 0.75, with a median of 0.73 recorded in 2022.
  • Year-over-year, Equity Ratio increased 17.66% in 2021 and then fell 0.99% in 2025.
  • Tracing BMRN's Equity Ratio over 5 years: stood at 0.71 in 2021, then increased by 1.64% to 0.72 in 2022, then rose by 0.23% to 0.72 in 2023, then increased by 11.86% to 0.81 in 2024, then dropped by 0.99% to 0.8 in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Equity Ratio are 0.8 (Q4 2025), 0.8 (Q3 2025), and 0.81 (Q2 2025).